1 / 22

Immunofluorescence Detection of Complement Activation Products C4d and C3d:

Immunofluorescence Detection of Complement Activation Products C4d and C3d: Cleveland Clinic Experience Carmela D. Tan August 12, 2009. AMR at the Cleveland Clinic. Describe the staining patterns of C4d and C3d in heart transplant biopsies

sook
Télécharger la présentation

Immunofluorescence Detection of Complement Activation Products C4d and C3d:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunofluorescence Detection of Complement Activation Products C4d and C3d: Cleveland Clinic Experience Carmela D. Tan August 12, 2009

  2. AMR at the Cleveland Clinic • Describe the staining patterns of C4d and C3d in heart transplant biopsies • Describe the clinical utility of C4d and C3d staining in the diagnosis of AMR • Report the prevalence of AMR in a single high-volume heart transplant center • Describe how regulation of complement correlates with clinical presentation

  3. Methods • Every single endomyocardial biopsy since November 2006 is routinely stained with C4d & C3d for clinical diagnosis • 4 or more pieces frozen for H&E and IF • Staining patterns: capillary vs perimyocytic, diffuse vs focal • Staining intensity : 0 to 3+ • Study period: November 2006 to December 2007 • In addition to C4d & C3d, for this study all available biopsies were also stained for the complement regulators CD55 (DAF) and CD59 (Protectin)

  4. Methods • Retrospective review of electronic medical records with follow-up until December 2008 - clinical evidence of allograft dysfunction • Cardiac allograft dysfunction was defined as: • A decline in left ventricular ejection fraction • A decrease in cardiac index • Elevation of right side cardiac pressures and • A need for inotropic support. • Serologic determination of anti-HLA antibodies in all C4d positive patients

  5. Results • 1511 EMBs • 330 adult patients (age: 20-73) • - 266 males; 64 females • Years after transplant • - 1 year or less: 50 • - 1-5 years: 241 • - >5 years: 39 • Average number of biopsies: 5

  6. C4d, C3d

  7. Cap and perimyocytic

  8. C4d only

  9. Perimyocytic only

  10. Results of 330 patients

  11. Only diffuse capillary staining is relevant when clinical and serologic data are correlated. Group 1 Group 2 Tan CD et al, Am J Transplant Epub 2009 Jul 16

  12. Correlation of C4d and C3d with DSA, allograft dysfunction and mortality Tan CD et al, Am J Transplant Epub 2009 Jul 16

  13. Tan CD et al, Am J Transplant Epub 2009 Jul 16

  14. Tan CD et al, Am J Transplant Epub 2009 Jul 16

  15. CD55 negative CD55 positive (1+) CD55 positive (3+) Tan CD et al, Am J Transplant Epub 2009 Jul 16

  16. Control group (n=264) Tan CD et al, Am J Transplant Epub 2009 Jul 16

  17. Group 1 Group 2 Group 3 Group 4 Tan CD et al, Am J Transplant Epub 2009 Jul 16

  18. Tan CD et al, Am J Transplant Epub 2009 Jul 16

  19. In summary, • A panel of C4d and C3d is more useful than C4d alone in the evaluation of AMR in heart transplants. • Presence of C4d and C3d correlates with DSA and cardiac allograft dysfunction. • Prevalence of AMR in this cohort: 5% • AMR can occur months to years after transplantation. • Regulators of complement activation CD55 and CD59 may provide a protective mechanism from complement-mediated damage to the allograft.

  20. Acknowledgements: Pathology: E Rene Rodriguez Heart and Vascular Institute: Randall C. Starling David O. Taylor Gonzalo Gonzalez-Stawinski Nicholas Smedira Lerner Research Institute: William M. Baldwin III Transplant Center: Diane Pidwell Lynn Klingman Antibody Mediated Rejection (AMR) in Heart Transplantation Tan CD et al, Am J Transplant Epub 2009 Jul 16

More Related